| Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. | |
| | |
MedLine Citation:
|
PMID: 17531625 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We have found that the use of levonorgestrel-releasing IUS results in a remarkable decrease in endometrial proliferation and a remarkable increase in apoptosis in the endometrium; therefore, it is effective for long-term management of menorrhagic women with uterine myomas because of the striking reduction in menorrhagia. This prompted us to characterize the effects of progesterone (P(4)) and progesterone receptor modulator (PRM) CDB2914 on uterine myoma growth. In vitro studies with cultured uterine leiomyoma cells and normal myometrial cells revealed that P(4) stimulated the proliferative activity in leiomyoma cells, but not in normal myometrial cells. P(4) increased EGF expression, whereas E(2) augmented EGF-R expression in leiomyoma cells, indicating that P(4) and E(2) act in combination to stimulate leiomyoma cell growth. P(4) also increased Bcl-2 expression and decreased TNF-alpha expression in those cells. Unlike the EGF expression, IGF-I expression in leiomyoma cells was inhibited by P(4). These results suggest that P(4) has dual actions on leiomyoma growth: one is to stimulate the growth through up-regulating EGF and Bcl-2 expression, and the other is to inhibit the growth through down-regulating IGF-I expression in the cells. By contrast, CDB2914 inhibited proliferation and stimulated apoptosis of leiomyoma cells without affecting normal myometrial cells. Furthermore, CDB2914 inhibited vascular endothelial growth factor and adrenomedullin expression in leiomyoma cells, but not in normal myometrial cells. The cell type-specific action of CDB2914 on leiomyoma cells, without affecting the surrounding normal myometrial cells, is meaningful for understanding the usefulness of CDB2914 in the medical treatment of uterine myomas. |
| | |
Authors:
|
Takeshi Maruo; Noriyuki Ohara; Hiroya Matsuo; Qin Xu; Wei Chen; Regine Sitruk-Ware; Elof D B Johansson |
Related Documents
:
|
22722055 - Antitumor activity of photo-stimulated zinc oxide nanoparticles combined with paclitaxe... 20430025 - Bag-1 enhances cell-cell adhesion, reduces proliferation and induces chaperone-independ... 1755815 - Growth factors as mediators of testicular cell-cell interactions. 1283495 - Localization of basic fibroblast growth factor (bfgf) in a metastatic cell line (at-3) ... 22183155 - Ototoxin-induced cellular damage in neuromasts disrupts lateral line function in larval... 10383055 - Substratum of pleiotrophin (hb-gam) stimulates rat cg-4 line oligodendrocytes to adopt ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2007-03-21 |
Journal Detail:
|
Title: Contraception Volume: 75 ISSN: 0010-7824 ISO Abbreviation: Contraception Publication Date: 2007 Jun |
Date Detail:
|
Created Date: 2007-05-28 Completed Date: 2007-10-02 Revised Date: 2010-02-04 |
Medline Journal Info:
|
Nlm Unique ID: 0234361 Medline TA: Contraception Country: United States |
Other Details:
|
Languages: eng Pagination: S99-103 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan. maruo@kobe-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Contraceptive Agents, Female
/
pharmacology Endometrium / blood supply, drug effects, metabolism Female Humans Intrauterine Devices, Medicated* Leiomyoma / drug therapy*, metabolism Levonorgestrel / pharmacology Norpregnadienes / pharmacology* Progesterone / metabolism Receptors, Progesterone / drug effects Uterine Neoplasms / drug therapy*, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptive Agents, Female; 0/Norpregnadienes; 0/Receptors, Progesterone; 0/ulipristal; 57-83-0/Progesterone; 797-63-7/Levonorgestrel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Endometrial effects of intrauterine levonorgestrel.
Next Document: Can endosonographers evaluate on-site cytologic adequacy? A comparison with cytotechnologists.